HIV AIDS News

However only about 18% of the 1.2 million Americans who might benefit from the medications got a prescription last year, according to Health and Human Services Secretary Alex Azar.

The new strain is a part of the same family of virus subtypes that have fueled the global HIV pandemic, according to Abbott Laboratories, which conducted the research with the University of Missouri.

Treatment advances are keeping people with the virus alive longer, and those who adhere to therapy are expected to live into their mid-70s or longer.

Chinese researchers used the tool to give a patient blood cells that were altered to resist the AIDS-causing virus, the Associated Press reported.

Less than 40% of Americans have ever had an HIV test.

Best known as the two-drug combo pill Truvada, PrEP prevents HIV from establishing a permanent infection in people exposed through sex or injection drug use, the CDC says.

The study of nearly 2,000 HIV-positive women in Washington, D.C., New York, Chicago and San Francisco who have been followed since 1994 found that many have been able to control their HIV levels, off and on.

The study provides conclusive evidence that the risk of transmission through sex is zero when virus levels are undetectable because antiretroviral therapy, or ART.

The treatment became popular after Kim Kardashian underwent the procedure on camera for her show Kim and Kourtney Take Miami in 2013.

The researchers called for more effective depression screening and integration of depression treatment into HIV primary care.

A 35-year-old Atlanta woman who contracted HIV as a newborn offered one of her kidneys to an HIV-positive stranger, and doctors at Johns Hopkins University School of Medicine performed the procedure on Monday.

A new government program hopes to address the urgent needs by getting more people tested for HIV and boosting treatment rates.

In only the second known case worldwide, a man is free of HIV after a stem cell transplant, doctors say.

After years of significant declines, the number of new HIV infections began to level off in 2013, the CDC says. The cause: Effective HIV prevention and treatments are not reaching those who could most benefit, according to the CDC.

Federal health officials Wednesday outlined how they plan to achieve the goal of no new HIV cases in the U.S. by 2030, announced by President Donald Trump in Tuesday evening’s State of the Union address.

A recent review studies from the last decade found no cases of HIV transmission when the HIV-positive partner was on drug "cocktails" that were keeping the virus suppressed.

In a study of gay men who did not have HIV who were given antiviral drugs protectively, the number of new HIV infections fell from 295 cases in the year before the program rollout to 221 cases the year after.

A combination of two HIV-fighting antibodies, given to small group of people with HIV, appears to suppress the virus for a few months even after the person stops taking the drugs. Researchers hope it means could one day people could stop taking daily pills for HIV.

HIV, AIDS, treatment, T cells, monoclonal antibody

More than two-thirds of HIV-associated heart disease occurs in sub-Saharan Africa and Asia Pacific regions, according to the study.

Experimental HIV Vaccine Promising in Early Trial By Robert PreidtHealthDay Reporter FRIDAY, July 6, 2018 (HealthDay News) -- An experimental HIVvaccine was safe and triggered strong immune responses in healthy adults and in monkeys, researchers report.They say it also protected two-thirds of monkeys against an HIV-like virus.Though results of animal studies are not always the same in humans, researchers are encouraged by this early-stage study, which included nearly 400 healthy people. For their next step, they are launching a new vaccine trial that will include 2,600 women in southern Africa who are at risk of HIV infection.The

The vaccine targets a vulnerable site on HIV -- the virus that causes AIDS -- and triggered antibody production in mice, guinea pigs and monkeys, according to researchers with the U.S. National Institute of Allergy and Infectious Diseases (NIAID).

The study found no difference in the risk for premature birth, low birth weight or other serious complications among those who didn't receive TDF and those who got TDF along with emtricitabine and lopinavir/ritonavir.

The new test may be able to detect early evidence of HIV antibodies in saliva as reliably as a blood test, according to the scientists who developed it.

Researchers say a once-a-week, slow-release pill may keep HIV infections under control and help prevent new HIV infections altogether.